SynBioBeta Speaker
Mario Fuenzalida
Lipock
CEO
Mario Fuenzalida is a second-time founder and the CEO of Lipock, with deep expertise in global Go-To-Market (G2M) strategies and scaling deeptech ventures. Having previously led international teams and raised venture capital for science-based models (The Earth Says), Mario specializes in bridging the gap between advanced research and mass-market industrial adoption.At Lipock, Mario drives the commercial strategy to replace synthetic additives with edible nanotechnology. By leveraging a proprietary nanolipid platform that reduces natural bioactive dosages by up to 45 times, he enables global CPG and cosmetic manufacturers to achieve cost-parity with synthetic ingredients. His leadership focuses on providing a scalable solution to the "2027 Regulatory Cliff," allowing brands to transition to clean-label products without sacrificing profit margins. A Hello Tomorrow 2026 Pioneer backed by GridX, Mario is redefining how green chemistry reaches global industrial scales.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Mario
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
